Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenretinide SCHEMBL839699 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL15703189 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL19121 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL10629371 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL4874840 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL11703 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL11704 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL13402304 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL9838209 | 1.00 | RBP4 (1.00) | RBP4ALDH1A1MAPTHIF1ACYP3A4 | |
| Fenretinide SCHEMBL17593527 | 0.99 | RBP4 (0.98) | RBP4ALDH1A1MAPTHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20080234238-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-09-25 | — | — | US | disclosed |
| US-20080167276-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-07-10 | — | — | US | disclosed |
| US-20080167275-A1 | COMPOSITION CONTAINING PROGESTIN, PHYTOESTROGEN, ESTROGEN AND VITAMIN D COMPOUND | RODRIGUEZ GUSTAVO C | 2008-07-10 | — | — | US | disclosed |
| US-20080167279-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGIC EFFECTS IN THE OVARIAN EPITHELIUM | RODRIGUEZ GUSTAVO C | 2008-07-10 | — | — | US | disclosed |
| US-20080167278-A1 | COMPOSITION CONTAINING PROGESTIN, PHYTOESTROGEN AND ESTROGEN | RODRIGUEZ GUSTAVO C | 2008-07-10 | — | — | US | disclosed |
| US-20080045488-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | NEW LIFE PHARMACEUTICALS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20070275940-A1 | Composition containing Vitamin D and phytoestrogens | NEW LIFE PHARMACEUTICALS INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213543-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF AGENTS THAT INDUCE BIOLOGIC RESPONSES | RODRIGUEZ GUSTAVO C | 2007-09-13 | — | — | US | disclosed |
| US-20050113351-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | RODRIGUEZ GUSTAVO C (US) | 2005-05-26 | — | — | US | disclosed |
| US-20040176336-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | RODRIGUEZ GUSTAVO C (US) | 2004-09-09 | — | — | US | disclosed |
| US-6765002-B2 | PREVENTING THE DEVELOPMENT OF EPITHELIAL OVARIAN CANCER BY ADMINISTERING COMPOUNDS IN AN AMOUNT CAPABLE OF INCREASING TGF- BETA EXPRESSION IN THE OVARIAN EPITHELIUM. HRT AND OCP REGIMENS COMPRISING SUCH COMPOSITIONS AND METHODS ARE | GUSTAVO RODRIGUEZ | 2004-07-20 | — | — | US | disclosed |
| US-20040106587-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | NEW LIFE PHARMACEUTICALS INC. | 2004-06-03 | — | — | US | disclosed |
| US-20030125229-A1 | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium | NEW LIFE PHARMACEUTICALS, INC. | 2003-07-03 | — | — | US | disclosed |
| US-6511970-B1 | Multiphasic hormonal regimen wherein at least one of the daily dosages has at least 0.5 mg of norgestrel and an estrogen component | NEW LIFE PHARMACEUTICALS INC. | 2003-01-28 | — | — | US | disclosed |
| US-20010044431-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | NEW LIFE PHARMACEUTICALS INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234238-A1 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | CYP24A1, VDR, CYP2R1 | RBP4 2298/4885ALDH1A1 4422/4885MAPT 2933/4885 |
| US-20080045488-A1 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | TGFB1, HDGF, TGFB2 | RBP4 298/4885ALDH1A1 1015/4885MAPT 4130/4885 |
| US-20040106587-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | HDGF, PGF, OGFRL1 | RBP4 382/4885ALDH1A1 929/4885MAPT 4413/4885 |
| US-20010044431-A1 | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium | HDGF, PGF, OGFRL1 | RBP4 382/4885ALDH1A1 929/4885MAPT 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.